NasdaqGS:NBIXBiotechs
Neurocrine Biosciences (NBIX) Earnings Surge Challenges Cautious Narratives On Margin Durability
Neurocrine Biosciences (NBIX) opened 2026 with Q1 revenue of US$814.5 million and basic EPS of US$1.97, while trailing 12 month figures sit at US$3.1 billion of revenue and EPS of US$6.71, setting a firm earnings-season backdrop. The company has seen quarterly revenue move from US$572.6 million in Q1 2025 to US$814.5 million in Q1 2026, with basic EPS shifting from US$0.08 to US$1.97 over the same period. Earnings growth of 118.6% over the past year and forecast EPS growth of about 21.1% per...